Influence of inflammatory dermatoses on the quality of life of HIV-positive patients
- Authors: Evdokimov E.Y.1, Ponezheva Z.B1, Sundukov A.V2, Svechnikova E.V3
-
Affiliations:
- Central Research Institute of Epidemiology
- A.I. Yevdokimov Moscow State University of Medicine and Dentistry
- Clinic № 1 of President Affairs of Russian Federation
- Issue: Vol 27, No 14 (2020)
- Pages: 109-112
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/313020
- DOI: https://doi.org/10.18565/pharmateca.2020.14.109-112
- ID: 313020
Cite item
Open Access
Access granted
Abstract
Background. Skin diseases in HIV-infected patients are considered the most common pathology, while in patients without HIV infection, inflammatory dermatoses (IDs) contribute to a significant decrease in the quality of life, the indicators of which can serve as a recommendation for starting treatment. Objective. Assessment of the quality of life indicators of the “physical and mental health” in HIV-positive and HIV-negative patients with IDs. Methods. The 285 patients with IDs were followed-up, among them 150 (52.6%) were HIV-positive (89 (59.3%) patients received antiretroviral therapy [ART], 61 [40.7%] patients were without ART), and the comparison group included 135 (47.4%) patients. There were 83 (55.3%) men in the HIV-infected group, 76 (56.3%) - in the comparison group; there were 67 (44.7%) women among HIV-infected patients, in the comparison group - 59 (43.7%) women. The mean age in the both groups was 27.9 years (minimum - 23 years, maximum - 43). The mean duration of a confirmed diagnosis of inflammatory dermatosis (psoriasis, atopic dermatitis) was 8.2 years (minimum - 1.7 years, maximum - 14 years); in the group of HIV-infected patients, the diagnosis of ID was recorded no later than 7 months before HIV detection; patients in both groups received comparable topical and systemic therapy for dermatoses. The mean duration of HIV infection in patients was 3.8 years (minimum - 1.2 years, maximum - 7 years), the duration of ART averaged 1.8 years (minimum - 1.1 years, maximum - 4.2). Results. In HIV-infected patients with ID, there was a significant decrease in the median PH («physical health») and MH («mental health») of the quality of life compared to HIV-negative patients with ID; a more pronounced decrease in indicators was observed in patients who did not receive treatment for HIV infection. Conclusion. The presence of ID in HIV-positive patients can serve as indication for the urgent administreation of ART.
Full Text
About the authors
E. Yu Evdokimov
Central Research Institute of Epidemiology
Email: evdokimovevg@yandex.ru
Cand. Sci. (Med.), Researcher of the Clinical Department of the Central Research Institute of Epidemiology of Rospotrebnadzor; Dermatovenereologist of the Department of Dermatovenereology and Cosmetology 26/28, per. Sivcev Vrazhek, Moscow 119002, Russian Federation
Zh. B Ponezheva
Central Research Institute of EpidemiologyMoscow, Russia
A. V Sundukov
A.I. Yevdokimov Moscow State University of Medicine and DentistryMoscow, Russia
E. V Svechnikova
Clinic № 1 of President Affairs of Russian FederationMoscow, Russia
References
- Trickey A., May M.T., Vehreschiid J.-J., et aI., Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV 2017;4(8):349-56. doi: 10.1016/S2352-3018(17)30066-8.
- Altman K., Vanness E., Westergaard R.P Cutaneous manifestations of human immunodeficiency virus: a clinical update. Curr Infect Dis Rep. 2015;17(3):464. doi: 10.1007/s11908-015-0464-y.
- Вольф К., Голдсмит Л.А., Кац С.И. и др. Дерматология Фицпатрика в клинической практике. Т. 1. Пер. с англ. М., 2012. С. 99-142. [Wolf K, Goldsmith L.A., et al. Fitzpatrick dermatology in clinical practice. Vol. 1. M., 2012. Р 99-142. (In Russ.)].
- Chawhan S.M., Bhat D.M., Solanke S.M. Dermatological manifestations in human immunodeficiency virus infected patients: Morphological spectrum with CD4 correlation. Indian J Sex Transm Dis AIDS. 2013;34(2):89-94. doi: 10.4103/0253-7184.120538.
- Евдокимов Е.Ю., Понежева Ж.Б., Сундуков А.В., Свечникова Е.В. Клинические и микробиологические особенности атопического дерматита у ВИЧ-позитивных пациентов (обзор литературы). 2020;27(8):18-23. Doi: 10.18565/ pharmateca.2020.8.18-23.
- Birdi G., Cooke R., Knibb R.C. Impact of atopic dermatitis on quality of life in adults: a systematic review and meta analysis. Int J Dermatol. 2020;59:e75-e91. doi: 10.1111/ijd.14763.
- Мурашкин Н.Н., Амбарчян Э.Т. Сравнительная оценка эффективности и безопасности ингибиторов TNFa и il12/23 в терапии псориаза у детей. Педиатрическая фармакология. 2018;15(6):455-63.
- Chernyshov P.V. The Evolution of Quality of Life Assessment and Use in Dermatology Dermatology. 2019;235(3):167-74. doi: 10.1159/000496923.
- Shahriar J., Delate T., Hays R.D., Coons S.J. Commentary on using the SF-36 or MOS-HIV in studies of persons with HIV disease. Health Qual Life Outcomes. 2003;1:25. doi: 10.1186/1477-7525-1-25.
- Ware J.E., Snow K.K., Kosinski M., Gandek B. SF-36 Health Survey. Manual and interpretation guide. The Health Institute, New England Medical Center. Boston, Mass. 1993.
- Riazi A., Hobart J.C., Lamping D.L., et al. Using the SF-36 measure to compare the health impact of multiple sclerosis and Parkinson's disease with normal population health profiles. J Neurol Neurosurg Psychiatry. 2003;74(6):710-14. doi: 10.1136/jnnp.74.6.710.
- Амирджанова В.Н., Горячев Д.В., Коршунов Н.И. и др. Н. Популяционные показатели качества жизни по опроснику SF-36 (результаты многоцентрового исследования качества жизни «Мираж»). Научно-практическая ревматология. 2008;(1):36-48.
Supplementary files
